title: Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
abstract: Inflammatory reactions in coronary plaques play an important role in the pathogenesis of acute atherothrombotic events. The most powerful class of lipid-lowering drugs available-statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors)--have additional actions, unrelated to cholesterol reduction, including anti-inflammatory and immunomodulatory properties. This study sought to determine if atorvastatin affects monocyte and lymphocyte activation in patients with unstable angina and mild primary hypercholesterolemia. Following a 4-weeks hypolipemiant-free baseline period, 22 patients-12 with unstable angina (UA) and 10 patients with stable coronary heart disease (SCHD) - were treated with Atorvastatin 20 mg/day. Lipopolysaccharide (LPS)-receptor (CD14) and HLA-DR expression on monocytes and beta-integrins (CD11b, 11c, 49d) on monocytes and lymphocytes were measured by flow cytometry before and after treatment with atorvastatin for 8 weeks. Monocyte CD11b, 11c and CD14 expression and T lymphocytes CD11b expression were significantly (p < 0.001) higher in UA patients before treatment when compared with that in SCHD patients. In patients with UA, they decreased markedly with atorvastatin treatment. The reduction in expression of adhesion molecule on monocytes and lymphocytes and the concentrations of CRP and sICAM-1 may crucially contribute to the clinical benefit of atorvastatin in coronary artery disease, independent of cholesterol lowering effects.
authors.affiliation: Department of Clinical Biochemistry-Immunology, University of Medicine and Pharmacy, Târgu Mureş, Romania. dobreanu@orizont.net
authors.forename: Minodora
authors.initials: M
authors.lastname: Dobreanu
authors.forename: D
authors.initials: D
authors.lastname: Dobreanu
authors.forename: Andrea
authors.initials: A
authors.lastname: Fodor
authors.forename: Anca
authors.initials: A
authors.lastname: Bacarea
mesh_terms: D000328:Adult; D000789:Angina, Unstable / Q000150:complications*; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000069059:Atorvastatin; D016022:Case-Control Studies; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000150:complications; D005260:Female; D005434:Flow Cytometry; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications* / Q000188:drug therapy*; D039001:Integrin alpha Chains / Q000187:drug effects* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D039001:Integrin alpha Chains; D011758:Pyrroles; D000069059:Atorvastatin